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Contraceptive implant technology dates back to the mid 1960s. Subdermal 
implants have been available in Finland since late 1983 and in at least 14 other 
countries at the present time. They provide a slow-release carrier of various 
progestins-hormones that have progesterone-like activity. The prototype in this 
field is Norplant, which is a set of silicone rubber (silastic) rods packed with 
crystalline levonorgestrel. It was developed under the auspices of the Population 
Council's Center for Biomedical Research and approved by the FDA December 
10, 1990. 
Norplant has been heralded as the first major contraceptive advance in over 
thirty years. Its development has been controversial with most of the testing being 
done on Third World women amid charges of "gross violations of medical 
ethics.'" It has been alleged that women were not told that the drug was 
experimental nor were they told ofthe possible dangers of Norplant. Indeed it has 
been reported that monetary incentives were paid to women for accepting the 
birth control method, that reporting of complications was discouraged by clinic 
staff, and that proper health care was withheld from women who experienced side 
effects. Funding for this project has come from the United States Agency for 
International Development, the Canadian Government, the United Nations 
Population Fund and private donors. 
The Norplant system is made up of six small, thin, flexible rods (2.4 mm in 
diameter and 34 mm long) made up of soft silastic tubing filled with a synthetic 
hormone called levonorgestrel (see Figure I). Each rod contains 36 mg. of the 
hormone levonorgestrel. They are inserted, in a fan-like pattern,just under the skin 
of the upper arm in a minor, in-office surgical procedure costing approximately 
$350.2 The silastic rods are non-biodegradable and must be removed after 5 years 
(3 years for Norplant 2). 
Small amounts of levonorgestrel diffuse continuously through the walls of the 
silastic capsules to maintain blood levels. It is said that "contraception" is provided 
within 24 hours of the insertion of the rods if they are inserted within the first 
64 Linacre Quarterly 
seven days of the menstrual cycle. It is promoted as a continuous contraceptive 
lasting as long as five years in duration. 
Levonorgestrel is a progestin which has progesterone-like properties. It is 
important to emphasize that it is not progesterone but rather a progestin which is 
synthetic and foreign to the body. This artificial hormone releases slowly over the 
five years in which the system is used. Blood levels of the levonorgestrel are much 
higher in the first 9 months (85 mcg/day) than they are over the remaining 51 
months (30 mcg/day). As a result, one can anticipate that the mechanism by 
which Norplant works would differ somewhat during the first year of use versus 
the latter years of use. 
As with other progestin-only "contraceptives", Norplant is thought to have 
three modes of action: 
I. It acts on the hypothalamus and the pituitary gland to suppress the LH surge 
which is responsible for ovulation. 
2. The cervical mucus should become viscous and scant making it less 
permeable to sperm. 
3. The endometrium shows signs of suppression. 
The suppression of ovulation by Norplant is highly irregular. During the first 
year of use, 11.1 percent of menstrual cycles have been found to be ovulatory. But, 
after the first year of use, the incidence of ovulatory cycles increases as the amount 
of hormone diffusion decreases averaging 46.3 percent in years 2 through 5 and 
66.8 percent thereafter.3 When levonorgestrel suppresses ovulation it works as a 
contraceptive agent. When it adequately interferes with the cervical mucus to 
prevent the sperm from penetrating the cervix, it is also acting contraceptively. 
However, there is very little data to show the significance ofthis latter mechanism.4 
The third mechanism of action, that action associated with its effects on the 
endometrium, are dramatic. In nearly 90 percent of endometrial samples, the 
endometrium is disturbed.s This mechanism of action renders Norplant an 
abortifacient. The exact incidence of its abortifacient properties is not yet known, 
however, it is clear that this mechanism exists and undoubtedly occurs.6 
The "contraceptive" effectiveness of Norplant is listed in Table 2. The 
effectiveness varies rather considerably with the weight of the individual woman. 
The highest effectiveness ratings of99.8 percent are in women who weigh less than 
110 pounds. If the woman weighs over 154 pounds that effectiveness decreases to 
only 91.5 percent. 
The discontinuation rates are also very high over the years in which Norplant is 
used. In the first year the discontinuation rate is about 19 percent. However, by the 
third year that increases to 50.4 percent and by the fifth year, 70.5 percent (see 
Table 3). 
The most significant side effect to Norplant is abnormal bleeding. The type of 
bleeding pattern a woman will have cannot be predicted. In addition, women may 
experience headache, nervousness, nausea, dizziness, enlargement of the ovaries 
with ovarian cyst (10 percent), dermatitis, acne, changes in appetite, weight 
changes, mastalgia (breast tenderness), hirsutism (excessive hair growth), hair loss 
and hyperpigmentation over the implant site. 
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The surgical scar under the arm and the silastic tubules which are seen 
underneath the skin, identify women as users of Norplant. It is possible that this 
may cause women who use Norplant to be respected less and to be more 
susceptible to being used as a sexual object. The scar may be conspicuous in certain 
types of dress. 
Norplant also will not protect against sexually transmitted diseases such as 
Chlamydia and Gonorrhea. Because the fear of pregnancy is greatly reduced in 
unmarried teenagers using Norplant, increased sexual activity will put these 
women at risk for permanent infertility, Herpes Simplex Type II and Acquired 
Immune Deficiency Syndrome (AIDS). 
One of the promoted advantages of the Norplant system is its capability of being 
used by women who would be otherwise non-compliant to other systems of birth 
control. This also provides it with one of its more controversial concerns. 
Hearings have been held in the Kansas Legislature on a bill that would pay 
welfare mothers $500 to get the implant. It would also pay for the Norplant, plus 
an annual check up and a $50 check per year. 
It has been promoted as the best contraceptive choice for teenagers because of 
its one-time only insertion capability.s 
Judge Howard Broadman of Tulare County Superior Court in Visalia, 
California ordered a convicted female child abuser to use Norplant as a condition 
placed upon the woman's probation. 
And recently, an editorial in the Philadelphia Inquirer suggested that a good 
way to fight poverty would be to pay black welfare recipients to use Norplant.9 
The odd thing about all of the above issues is that organizations like the 
American Civil Liberties Union (ACLU) and advocates of abortion such as 
syndicated columnist, Ellen Goodman, have cast the argument that the 
government has no right to dictate birth control use. Unfortunately, the Catholic 
Church has been relatively silent on these issues. 
A good summary of the Norplant debate from a Catholic perspective has been 
written by Sr. Renee Mirkes, a consultant to the Pope John Center. JO She writes: 
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The Catholic Church enters the Norplant debate with an antithetical set of premises 
and conclusions. The practice of contraception, using Norplant or any other artificial 
contraceptive, apart from any regrettable circumstances associated with its use, is 
primarily morally objectionable because the act of contraception, in and of itself, is evil. 
This is so because contraceptive intercourse deliberately acts against the basic human 
good of procreation, a good that, by God's arrangement, is meant to be fostered or 
respected in every engagement in or abstention from marital intercourse. Furthermore, in 
the case of a birth control drug which is also an abortifacient, the destruction of the basic 
good of human life is risked as well. Although further evil uses - such as threats to a 
woman's health - may compound the evil of contraception, the moral status of 
contraception does not originate primarily from these. 
In other words, it is not as if the morality of using Norplant depends on whether it 
results in additional evils such as a threat to a woman's health, deprivation of user-
control, discrimination against women by making them solely responsible for family 
planning, etc.; contraception is a moral evil by virtue of its very nature. It destroys human 
goods which, when respected or actively embraced, contributes to a basic dimension of 
personal fulfillment. God has designed marriage and human love within marriage in such 
a way as to provide a husband and wife, in the context of the most intimate expression 
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of their reciprocal self-gifting, to imitate Him and His divine manner of loving, i.e., to 
engage in a love that is faithful, total, selfless and fruitful. 
It should come as no surprise to a reflective person that failure to exercise a marital love 
that is at once life-giving and love-giving might result in all sorts of undesirable 
consequences or auxiliary evils. But even if none of these were ever associated as direct 
results of contraception or even if they never occurred, the act of contraception would still 
take its silent toll on the human goal of all married love; the ever-expanding growth and 
personal, familial and societal fulfillment and well-being. 'o 
FIGURE I: Diagramatic sketch of Norplant 
implants placed in the inner aspects 
of the left upper arm. 
FIGURE J: Diagramatic sketch of Norplant implants placed in the inner aspects of the left upper arm. 
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TABLE 1 
FREQUENCY OF OVULATIONI 
FIRST SEVEN YEARS 
NORPLANT USERS2 
OVULATORY ANOVULATORY UNCERTAIN 
YEAR N % N % N % 
I 3 Il.l 22 81.5 2 7.4 
2 13 61.9 6 28.6 2 9.5 
3 10 27.8 23 63.9 3 8.3 
4 10 43.5 12 52.2 4.3 
5 25 52.1 22 45.8 I 2.1 
6 14 73.7 5 26.3 a 0.0 
7 9 60.0 5 33.3 6.7 
I thru 7 84 44.4 95 50.3 10 5.3 
I. Based on luteal phase plasma progesterone levels. 
2. From: ("roxallo. H.B.. Dial. S .. Pavel. M .. ct al : Plasma Progcsterone Levels During Long Term Treatment wi th 
LcvonorgL."trcl Silastic Implants. Acta Endocrin . 101:307-311. 1982. 
TABLE 2 
EFFECTIVENESS OF NORPLANT 
CUMULATIVE PREGNANCY RATES PER 100 USERSI 
BY WEIGHT CLASS 
5 YEAR CUMULATIVE 
CONTRACEPTIVE 
WEIGHT CLASS PG.RATE EFFECTIVENESS 
< 110 LBS. 0.2 99.8 
110 - 130 LBS. 3.4 96.6 
131-153 LBS. 5.0 95.0 
.? 154 LBS. 8.5 91.5 
I. From: Woutersl. T.B.: The Norplant System of Contraception. lnL 1. Fenilily. Supp (3): 51-56,1991. 
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TABLE 3 
DISCONTINUATION AND CONTINUATION 
RATES (PER tOO USERS), NOR PLANT 
CUMULATIVE RATE BY YEAR 
STATUS 2 3 4 
D/ C for Menstrual Irregularities 9.1 17.0 21.9 25.2 
D/C for Medical Reasons 6.0 11.6 15.7 19.7 
DIC for Personal Reasons 4.6 7.7 24.0 34.7 
Continuation Rates 81.0 62.7 49.6 38.0 
I. from: Woutersz. T.B., The Norplant System of Contraception. Int. J. Fenilily. Supp (3): 5 1-66, 1991. 
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